1. Home
  2. NOTV vs RVPH Comparison

NOTV vs RVPH Comparison

Compare NOTV & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NOTV
  • RVPH
  • Stock Information
  • Founded
  • NOTV 1974
  • RVPH 2006
  • Country
  • NOTV United States
  • RVPH United States
  • Employees
  • NOTV N/A
  • RVPH N/A
  • Industry
  • NOTV Biotechnology: Pharmaceutical Preparations
  • RVPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • NOTV Health Care
  • RVPH Health Care
  • Exchange
  • NOTV Nasdaq
  • RVPH Nasdaq
  • Market Cap
  • NOTV 126.3M
  • RVPH 87.6M
  • IPO Year
  • NOTV 1997
  • RVPH N/A
  • Fundamental
  • Price
  • NOTV $4.22
  • RVPH $1.58
  • Analyst Decision
  • NOTV Strong Buy
  • RVPH Strong Buy
  • Analyst Count
  • NOTV 3
  • RVPH 5
  • Target Price
  • NOTV $5.92
  • RVPH $12.00
  • AVG Volume (30 Days)
  • NOTV 1.5M
  • RVPH 4.6M
  • Earning Date
  • NOTV 02-05-2025
  • RVPH 11-14-2024
  • Dividend Yield
  • NOTV N/A
  • RVPH N/A
  • EPS Growth
  • NOTV N/A
  • RVPH N/A
  • EPS
  • NOTV N/A
  • RVPH N/A
  • Revenue
  • NOTV $490,739,000.00
  • RVPH N/A
  • Revenue This Year
  • NOTV $7.14
  • RVPH N/A
  • Revenue Next Year
  • NOTV $5.73
  • RVPH N/A
  • P/E Ratio
  • NOTV N/A
  • RVPH N/A
  • Revenue Growth
  • NOTV N/A
  • RVPH N/A
  • 52 Week Low
  • NOTV $1.23
  • RVPH $0.60
  • 52 Week High
  • NOTV $11.42
  • RVPH $4.83
  • Technical
  • Relative Strength Index (RSI)
  • NOTV 48.58
  • RVPH 44.55
  • Support Level
  • NOTV $4.17
  • RVPH $1.79
  • Resistance Level
  • NOTV $5.67
  • RVPH $2.17
  • Average True Range (ATR)
  • NOTV 0.55
  • RVPH 0.27
  • MACD
  • NOTV -0.11
  • RVPH -0.04
  • Stochastic Oscillator
  • NOTV 22.87
  • RVPH 35.87

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: